News & Updates

R3 Vascular Reports the Initiation of Its First-In-Human Clinical Study

09/15/2021

“Clinical development of our bioresorbable sirolimus-eluting scaffold for treating peripheral arterial disease (PAD) is proceeding ahead of schedule and achieving outstanding procedural results,” said Kamal Ramzipoor, CEO of R3 Vascular. Excerpt from the Press Release: MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and…

Read More

Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations

09/15/2021

Excerpt from the Press Release: SAN DIEGO, Sept. 7, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD). Patients whose tumors are HRD-positive may be…

Read More

Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19

09/15/2021

Excerpt from the Press Release: SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection. In preclinical studies, Tempol has been shown to have antiviral, anti-inflammatory and antioxidant activity.…

Read More

Researchers replicate COVID-19 infections with lab-grown ‘mini-lungs’

09/15/2021

Excerpt from the Press Release: Researchers at the University of California, San Diego (UCSD) have grown miniature human lungs in a lab dish that they say come the closest to mimicking the real thing—complete with all the myriad cell types found in the body. The small organoids of human tissue could help rapidly iterate the…

Read More

Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients

09/14/2021

Excerpt from the Press Release: First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil. Second site scheduled to start enrolling within one week, with multiple additional sites coming online within one month. SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal…

Read More

Tantu and Ginkgo Bioworks Announce Partnership to Engineer a Living Biotherapeutic for Gastrointestinal Healing

09/14/2021

Tantu will leverage Ginkgo’s foundries to accelerate strain construction as a key step toward human clinical trials Excerpt from the Press Release: BOSTON, Sept. 7, 2021 /PRNewswire/ — Tantu, a company engineering living biotherapeutic products to treat gastrointestinal diseases, and Ginkgo Bioworks (“Ginkgo”), which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the…

Read More

The McQuade Center for Strategic Research and Development Enters Agreement with Sentinel Oncology to Develop Breakthrough Treatment for Fragile X Syndrome

09/14/2021

Excerpt from the Press Release: RINCETON, N.J.–(BUSINESS WIRE)–The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company. The McQuade Center for Strategic Research and Development at Otsuka in the…

Read More

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

09/14/2021

Excerpt from the Press Release: One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff – – Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET – PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 05, 2021 (GLOBE…

Read More

Sentien Biotechnologies Partners with BARDA to Evaluate High Dose Cohort in Phase 1/2 Trial of SBI-101 for Treatment of Acute Kidney Injury Associated with Sepsis

09/13/2021

Excerpt from the Press Release: Collaboration Under BARDA DRIVe Solving Sepsis Program to also Support Key Regulatory Path Activities to Advance Development of SBI-101 Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the…

Read More

Arch Therapeutics Partners with Lovell Government Services to Expand Distribution Capabilities

09/13/2021

Excerpt from the Press Release: Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced that it has entered into a non-exclusive distribution agreement with Lovell Government Services (“LGS”), a Service-Disabled Veteran-Owned Small Business (“SDVOSB”), to support and drive sales through the…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives